BR112015007641A8 - Tratamento da doença de alzheimer branda e moderada - Google Patents

Tratamento da doença de alzheimer branda e moderada

Info

Publication number
BR112015007641A8
BR112015007641A8 BR112015007641A BR112015007641A BR112015007641A8 BR 112015007641 A8 BR112015007641 A8 BR 112015007641A8 BR 112015007641 A BR112015007641 A BR 112015007641A BR 112015007641 A BR112015007641 A BR 112015007641A BR 112015007641 A8 BR112015007641 A8 BR 112015007641A8
Authority
BR
Brazil
Prior art keywords
treatment
mild
alzheimer disease
moderate alzheimer
moderate
Prior art date
Application number
BR112015007641A
Other languages
English (en)
Other versions
BR112015007641A2 (pt
Inventor
Orlandi Cesare
Clark David
M Grimes Imogene
Carmen Valcarce Lopez Maria
J Kostura Matthew
Original Assignee
Vtv Therapeutics Llc
Transtech Pharma Llc
Vtvx Holdings I Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc, Transtech Pharma Llc, Vtvx Holdings I Llc filed Critical Vtv Therapeutics Llc
Publication of BR112015007641A2 publication Critical patent/BR112015007641A2/pt
Publication of BR112015007641A8 publication Critical patent/BR112015007641A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)

Abstract

TRATAMENTO DA DOENÇA DE ALZHEIMER BRANDA E MODERADA. A presente invenção refere-se aos métodos de tratamento usando a [3-(4-{2-butil-1-[4-(4-cloro-fenóxi)-fenil]-1H-imidazol-4-il}-fenóxi)-propil]-dietil amina ("COMPOSTO I") ou um seu sal farmaceuticamente aceitável. Em diversas modalidades, os métodos de tratamento incluem o tratamento da demência branda a moderada do tipo Alzheimer, a diabetes, a insônia, e outras indicações. A presente invenção também se refere às composições farmacêuticas que compreendem o COMPOSTO I ou um sal farmaceuticamente aceitável dele.
BR112015007641A 2012-10-05 2013-10-02 Tratamento da doença de alzheimer branda e moderada BR112015007641A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261710229P 2012-10-05 2012-10-05
PCT/US2013/062964 WO2014055588A1 (en) 2012-10-05 2013-10-02 Treatment of mild and moderate alzheimer's disease

Publications (2)

Publication Number Publication Date
BR112015007641A2 BR112015007641A2 (pt) 2017-07-04
BR112015007641A8 true BR112015007641A8 (pt) 2018-04-03

Family

ID=49354960

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015007641A BR112015007641A8 (pt) 2012-10-05 2013-10-02 Tratamento da doença de alzheimer branda e moderada

Country Status (15)

Country Link
EP (1) EP2903606A1 (pt)
JP (2) JP6566868B2 (pt)
KR (1) KR20150064743A (pt)
CN (2) CN104703592A (pt)
AU (2) AU2013327450B2 (pt)
BR (1) BR112015007641A8 (pt)
CA (1) CA2886785C (pt)
EA (1) EA201590687A1 (pt)
HK (1) HK1207004A1 (pt)
IL (1) IL237730B (pt)
IN (1) IN2015DN03734A (pt)
MX (1) MX2015003732A (pt)
NZ (2) NZ705813A (pt)
SG (2) SG11201502210VA (pt)
WO (1) WO2014055588A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) * 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
EP3864008A1 (en) 2018-10-10 2021-08-18 vTv Therapeutics LLC Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine
WO2020086388A1 (en) * 2018-10-22 2020-04-30 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of cognitive impairment
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
CN114957470B (zh) * 2021-11-12 2023-01-17 深圳市人民医院 靶向rage的纳米抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1482931T3 (da) * 2002-03-05 2011-12-19 Transtech Pharma Inc Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE
ZA200508300B (en) * 2003-05-20 2007-03-28 Transtech Pharma Inc RAGE antagonists as agents to reverse amyloidosis and diseases associated therewith
EP1707203A1 (en) * 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
CN101663280A (zh) * 2007-04-05 2010-03-03 转化技术制药公司 [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ
US7884219B2 (en) * 2007-04-05 2011-02-08 Transtech Pharma, Inc. Crystalline forms of [3-(4- {2-butyl- 1 -[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine
WO2008153957A1 (en) * 2007-06-07 2008-12-18 The Trustees Of Columbia University In The City Of New York Uses of rage antagonists for treating obesity and related diseases
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
EP2638052B1 (en) * 2010-11-08 2017-03-22 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof

Also Published As

Publication number Publication date
IL237730B (en) 2018-10-31
AU2013327450B2 (en) 2018-07-12
CN110292638A (zh) 2019-10-01
JP2019163301A (ja) 2019-09-26
CA2886785C (en) 2022-06-07
NZ739521A (en) 2019-06-28
IN2015DN03734A (pt) 2015-09-18
JP2015535850A (ja) 2015-12-17
EP2903606A1 (en) 2015-08-12
AU2013327450A1 (en) 2015-05-14
CN104703592A (zh) 2015-06-10
SG10201702648YA (en) 2017-04-27
KR20150064743A (ko) 2015-06-11
MX2015003732A (es) 2015-09-23
WO2014055588A1 (en) 2014-04-10
NZ705813A (en) 2018-02-23
CA2886785A1 (en) 2014-04-10
BR112015007641A2 (pt) 2017-07-04
JP6894940B2 (ja) 2021-06-30
EA201590687A1 (ru) 2015-09-30
JP6566868B2 (ja) 2019-08-28
HK1207004A1 (en) 2016-01-22
SG11201502210VA (en) 2015-04-29
AU2018203434A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
BR112015007641A8 (pt) Tratamento da doença de alzheimer branda e moderada
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
BR112015004205A2 (pt) sulfamoil-arilamidas e o uso das mesmas como medicamentos para o tratamento da hepatite b
BR112013023517A2 (pt) "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica"
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112015017997A8 (pt) amidas de quinolina e quinoxalina como moduladores de canais de sódio, composição farmacêutica que as compreende e uso
BR112015019720B8 (pt) Inibidores de (benzil-ciano-metil)-amidas de ácido 2-azabiciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c e composição farmacêutica
BR112015022566A2 (pt) composto e composição farmacêutica
BR112013017779A2 (pt) derivados de oxazina e seu uso no tratamento de distúrbios neurológicos
BR112014000371A2 (pt) derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
BR112013000920A2 (pt) compostos para a redução de produção de beta-amiloide
BR112014026703A2 (pt) inibidores de dna-pk
BR112013032391A2 (pt) antagonistas de trpv4
BR112015004529A8 (pt) alcóxi pirazóis, seu uso como ativadores de guanilato ciclase solúvel e composição farmacêutica que os compreende
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
BR112014015845A8 (pt) derivados de azetidina, composições farmacêuticas e seu uso
BR112014031091A2 (pt) Derivados de piperidina para agonista de gpr119
BR122018070508B8 (pt) derivados de arilamida triazol-substituída e seu uso
BR112012003464B8 (pt) compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica
BR112014010401A8 (pt) Inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
BR112015007647A2 (pt) derivados de quetamina

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: VTV THERAPEUTICS LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: VTVX HOLDINGS I LLC (US)

B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: VTV THERAPEUTICS LLC (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2534 DE 30-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]